Format

Send to

Choose Destination
Fertil Steril. 2017 Mar;107(3):781-787.e3. doi: 10.1016/j.fertnstert.2016.12.003. Epub 2017 Feb 8.

Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study.

Author information

1
Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
2
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
3
Department of Thoracic Surgery, Otto-Wagner-Spital, Vienna, Austria.
4
University Clinic of Internal Medicine III, Department of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
5
University Clinic of Internal Medicine III, Department of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria. Electronic address: Michaela.Bayerle-Eder@meduniwien.ac.at.

Abstract

OBJECTIVE:

To study sexual function, quality of life, and depression in men, whose female partners are undergoing double-blind placebo-controlled randomized treatment for hypoactive sexual desire disorder (HSDD).

DESIGN:

Open prospective cohort study of 22 weeks.

SETTING:

Academic medical center.

PATIENT(S):

Male partners of 30 premenopausal and postmenopausal women with HSDD.

INTERVENTION(S):

Baseline, 3-month, and 5-month assessment (for 8 weeks each) of male response to female partner's use of oxytocin nasal spray (32 IE) and placebo within 50 minutes before sexual intercourse.

MAIN OUTCOME MEASURE(S):

Primary outcome parameters were Sexual Life Quality Questionnaire-Male, Sexual Activity Record, Partner Performance Questionnaire, and Hamilton Depression Scale.

RESULT(S):

Male Sexual Life Quality questionnaire improved significantly from -7.4 ± 9.9 at baseline to 8.2 ± 12 with female partners' treatment with oxytocin nasal spray and to 10.8 ± 13.8 with placebo. Frequency of intercourse improved slightly but not significantly from 6.3 ± 3.9 at baseline to 7.3 ± 4 with female oxytocin therapy, but not with placebo. Male desire and arousal remained stable throughout the study period. Evaluation of female partners' performance by men improved significantly from 8.9 ± 2.8 at baseline to 10.6 ± 2.2 with oxytocin and to 11.2 ± 2.6 with placebo.

CONCLUSION(S):

Female treatment with either oxytocin or placebo for HSDD significantly improves male sexual quality of life and evaluation of female partner's sexual performance with no difference between oxytocin and placebo on any outcome parameters. A nonsignificant improvement was seen in the frequency of intercourse, male arousal, desire, satisfaction, and Hamilton depression scale.

CLINICAL TRIAL REGISTRATION NUMBER:

NCT02229721.

KEYWORDS:

Male sexual function; hypoactive sexual desire disorder; oxytocin; quality of life

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center